texas oncology more breakthroughs. more victories

Fort Worth Cancer Center Research and Clinical Trials

Texas Oncology-Fort Worth Cancer Center participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Fort Worth Cancer Center (Expand)

Biliary Cancer

STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308)

A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308) Read Moreabout STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308)

Phase: III

Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302) Read Moreabout Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)

Phase: III

STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements Read Moreabout STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

Phase: II

Breast Cancer

Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

Phase: I

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer

A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201) Read Moreabout Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer

Phase: II

Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002) Read Moreabout Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

Phase: III

ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer

A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303) Read Moreabout ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer

Phase: III

Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)

A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001) Read Moreabout Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)

Phase: III

Ph2 clinical trial of BNT327 in combo with treatment in breast cancer

A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02) Read Moreabout Ph2 clinical trial of BNT327 in combo with treatment in breast cancer

Phase: II

Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001) Read Moreabout Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

Phase: III

Ph3 GDC-9545 ER+ HER2- BC (lidERA)

A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784) Read Moreabout Ph3 GDC-9545 ER+ HER2- BC (lidERA)

Phase: III

Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast

A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657) Read Moreabout Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast

Phase: III

Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer

An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010) Read Moreabout Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer

Phase: II

Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase: III

Ph3 study of standard endocrine therapy with breast cancer

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422) Read Moreabout Ph3 study of standard endocrine therapy with breast cancer

Phase: III

Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase: III

Cervical Cancer

Ph3 robotic Hysterectomy ROCC

(GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) Read Moreabout Ph3 robotic Hysterectomy ROCC

Phase: III

Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01) Read Moreabout Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

Phase: I/II

GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer

A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00) Read Moreabout GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer

Phase: III

Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE)

Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002) Read Moreabout Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE)

Phase: III

Colon Cancer

Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001) Read Moreabout Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

Phase: I/II

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002) Read Moreabout Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

Phase: III

Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

Phase: III

Endometrial Cancer

Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

Phase: I

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II

Ph3 Selin P53 Endo Carcinoma

A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042) Read Moreabout Ph3 Selin P53 Endo Carcinoma

Phase: III

Ph3 study of GOG-3104 with endometrial cancer

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769) Read Moreabout Ph3 study of GOG-3104 with endometrial cancer

Phase: III

Esophageal Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

Phase: I

Fallopian Tube Cancer

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Gastric Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

Phase: I

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Phase: II

Head and Neck Cancer

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Phase: II

STAR Ph3 study to evaluate to treat patients with HNSCC

A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) Read Moreabout STAR Ph3 study to evaluate to treat patients with HNSCC

Phase: III

Ph3 study of pembro in HNSCC in the disease without curative therapy available

A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03) Read Moreabout Ph3 study of pembro in HNSCC in the disease without curative therapy available

Phase: III

Leukemia

Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060)

Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032) Read Moreabout Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060)

Phase: II

Liver Cancer

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Lung Cancer

Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001) Read Moreabout Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

Phase: I/II

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC

A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153) Read Moreabout Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC

Phase: II

Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201) Read Moreabout Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

Phase: II

Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005) Read Moreabout Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

Phase: II

Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17)

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017) Read Moreabout Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17)

Phase: II

Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)

A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012) Read Moreabout Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)

Phase: II

Ph3 Tarlatamab in combo with Durvalumab ES-SCLC

A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041) Read Moreabout Ph3 Tarlatamab in combo with Durvalumab ES-SCLC

Phase: III

STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217) Read Moreabout STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

Phase: III

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)

A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007) Read Moreabout Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)

Phase: III

Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4)

A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721) Read Moreabout Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4)

Phase: II/III

ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Read Moreabout ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase: III

Lymphomas

Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma

A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003) Read Moreabout Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma

Phase: III

Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma

A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145) Read Moreabout Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma

Phase: III

Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3)

A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202] Read Moreabout Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3)

Phase: II

Myelofibrosis

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Phase: I

Ovarian Cancer

Ph1 NXP800 Ovarian Cancer

A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (NXP800-101) Read Moreabout Ph1 NXP800 Ovarian Cancer

Phase: I

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6)

A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002) Read Moreabout Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6)

Phase: II

Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)

A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301) Read Moreabout Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)

Phase: III

Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer

A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02) Read Moreabout Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer

Phase: III

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Pancreatic Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203) Read Moreabout Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors

Phase: II

Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)

A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302) Read Moreabout Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)

Phase: III

Peritoneal Cancer

Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)

Phase: III

Prostate Cancer

Ph3 study of MK-5684 versus alternative NHA in mCRPC

A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004) Read Moreabout Ph3 study of MK-5684 versus alternative NHA in mCRPC

Phase: III

Rectal Cancer

Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002) Read Moreabout Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

Phase: III

Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

Phase: III

Solid Tumors

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001) Read Moreabout Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway

Phase: I/II

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01) Read Moreabout Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

Phase: I/II

STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors

A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001) Read Moreabout STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors

Phase: I/II

STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01) Read Moreabout STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Phase: IV

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

Urothelial Cancer

Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01) Read Moreabout Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors

Phase: I/II

Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082) Read Moreabout Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder

Phase: I/II

Uterine Cancer

Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101) Read Moreabout Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors

Phase: I

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II